Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zolmitriptan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Zolmitriptan | DRUG | 5mg Nasal Spray |
| Placebo | DRUG | - |
Inclusion Criteria: * Subject has an established diagnosis of migraine headache, with or without aura * Subject has a medical history indicating the presence of migraine attacks for at least 1 year before the start of the trial or a minimum of 2 and maximum of 6 migraine attacks per month on averag...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant |
| Pfizer Inc. | PFE | 9 | PHASE3 | Rimegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab Dose 1 |
| Ki Health Partners. LLC | RVNC | 1 | - | Daxibotulinumtonix A |
Zolmitriptan is a small molecule drug used for the treatment of migraine. It is being developed by AstraZeneca PLC (AZN) and is currently in Phase 3 clinical development. The drug is administered as a nasal spray and has been studied in a completed Phase 3 trial.
Zolmitriptan is a small molecule drug that targets serotonin receptors, specifically the 5-HT1B/1D receptors, which are involved in the constriction of cranial blood vessels and the inhibition of pro-inflammatory neuropeptide release, providing relief from migraine symptoms.
Zolmitriptan is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker AZN. The drug is currently in Phase 3 clinical development for the treatment of migraine.
Zolmitriptan is in Phase 3 clinical development. It has completed one Phase 3 trial, which was a randomized, double-blind, placebo-controlled study involving 2,114 participants. The drug is not yet approved and remains investigational.
Zolmitriptan has been studied in a completed Phase 3 clinical trial with the identifier NCT00617747. This trial, titled 'Efficacy and Tolerability of Zolmitriptan Nasal Spray,' enrolled 2,114 participants with migraine and was a randomized, double-blind, placebo-controlled study.
Zolmitriptan is a specific drug and is not known by any alternative names. It belongs to the class of triptans, which are used to treat migraines, but it is a distinct compound developed by AstraZeneca.